Elsevier

Journal of Infection

Volume 72, Issue 6, June 2016, Pages 706-712
Journal of Infection

Interferon-gamma release assays in patients with Mycobacterium kansasii pulmonary infection: A retrospective survey

https://doi.org/10.1016/j.jinf.2016.03.011Get rights and content

Highlights

  • The positive rate of IGRAs in patients with M. kansasii was approximately 30%.

  • M. kansasii infection induced less activation of IGRAs than tuberculosis infection.

  • Previous TB is the only factor affecting IGRA positivity in patients with M. kansasii.

  • The cross-reactivity of TB specific antigens in cases with M. kansasii may be weak.

Summary

Objectives

Interferon-gamma release assays (IGRAs) can be positive in patients infected with Mycobacterium kansasii (M. kansasii), which carries some of Mycobacterium tuberculosis specific antigens adopted for IGRAs. Our aim is to evaluate positive rate and factors associated with positive IGRAs in patients with M. kansasii pulmonary infection.

Methods

We retrospectively investigated 105 M. kansasii cases in which IGRAs were performed before or ≦14 days after treatment initiation. Clinical characteristics including a history of tuberculosis, radiographic features and laboratory data were collected from medical records.

Results

Positive rate of each IGRA was 25.9% (15/58) in QuantiFERON TB-Gold (QFT-G), 31.8% (7/22) in QuantiFERON-TB Gold In Tube (QFT-GIT), and 33.3% (7/21) in T-SPOT. TB (T-SPOT). After excluding cases having a history of tuberculosis, positive rate of each IGRA decreased to 19% (8/42) in QFT-G, 20% (3/15) in QFT-GIT, and 18.8% (3/16) in T-SPOT. The multivariate analysis revealed that only previous tuberculosis was significantly associated with positive IGRAs (odds ratio, 4.758; 95% confidence interval, 1.73–13.05; p = 0.002).

Conclusions

Positive rates of IGRAs were low in patients with M. kansasii, especially in those without previous tuberculosis. M. kansasii pulmonary infection alone might induce less interferon-gamma production with the antigens.

Introduction

Interferon-gamma release assays (IGRAs), widely in use to diagnose tuberculosis (TB) infection, are immunologic assays that measure interferon-gamma (IFN-γ) response to TB specific antigens such as early secretory antigenic target-6 (ESAT-6), culture filtrate protein-10 (CFP-10), and TB7.7. IFN-γ stimulated with ESAT-6 and CFP-10 is measured by enzyme-linked immunosorbent assay (ELISA) in QuantiFERON TB-Gold (QFT-G; Cellestis [a Qiagen company], Valencia, CA). Recently, QFT-TB Gold In Tube (QFT-GIT; Cellestis [a Qiagen company], Valencia, CA), which stimulates peripheral lymphocyte with ESAT-6, CFP-10, and TB7.7 became commercially available in many countries. T-SPOT. TB (T-SPOT; Oxford Immunotec Ltd., Abingdon, UK) is the enzyme-linked immunospot (ELISPOT) assay which counts the number of effector T cells that produce INF-γ by stimulation of ESAT-6 and CFP-10. These assays are highly specific and sensitive for TB infection compared with tuberculin skin test (TST).1, 2

Though the prevalence of nontuberculous mycobacterium (NTM) varies according to the geographic region, some epidemiologic data suggest numbers of NTM is increasing in developed countries.3, 4, 5, 6 Pulmonary infection by Mycobacterium kansasii (M. kansasii) is the second most popular NTM infection next to Mycobacterium avium complex in Australia and Japan.3, 6 In addition, M. kansasii is the second most isolated NTM from respiratory samples in some European countries including the United Kingdom, Slovakia, and Poland, accounting for 11%, 36% and 35%, respectively.4 Cavitation in upper pulmonary lobes is a common radiographic feature of M. kansasii pulmonary infection, which resembles pulmonary TB.7, 8 As a result, IGRAs are often performed in undiagnosed M. kansaii cases.

A few species of NTM such as M. kansasii, Mycobacterium marinum, and Mycobacterium szulgai possess CFP-10 and ESAT-6 in their DNA sequence.9, 10 Therefore, IGRAs can be positive in patients infected with these mycobacteria although in practice we had an impression that positive rate seems low in M. kansasii infection. In this retrospective survey we investigated positive rate of IGRAs and factors contributing to positive IGRAs in patients with M. kansasii infection.

Section snippets

Methods

We analyzed M. kansasii pulmonary infection cases which met the diagnostic criteria of NTM by the American Thoracic Society/the Infectious Diseases Society of America (ATS/IDSA)11 diagnosed at National Hospital Organization Tokyo National Hospital between January 2003 and April 2015. M. kansasii was isolated and identified from respiratory specimens (sputum or bronchial washing fluid) in all cases. The cases diagnosed with simultaneous TB and M. kansasii coinfection were excluded. We selected

Statistical analysis

Data are shown as the number of patients with percentage or the average with standard deviation. Fisher's exact test or Pearson's chi-square test was used to compare patients' characteristics. The risk factors for positive IGRAs were evaluated by univariate and multivariate analysis. The candidate factors, including age, previous TB infection, peripheral lymphocyte count, and radiographic features, were chosen for evaluation based on the reported factors affecting IGRAs result in patients with

Patient characteristics and result of IGRAs

Among 157 cases with positive M. kansasii culture, 140 cases met the diagnostic criteria of NTM by ATS/IDSA. 33 cases without IGRAs and 2 cases co-infected with TB were excluded. Among 105 cases analyzed in this study, QFT-G was performed in 59 cases, QFT-GIT in 25 cases, and T-SPOT in 21 cases (Fig. 1).

Clinical characteristics of patients are shown in Table 1. Immunosuppressants including corticosteroids were used in 4 QFT-G cases (3 with interstitial pneumonia and one with bronchial asthma),

Discussion

This is the first study that evaluates the positive rate of three different IGRAs in patients with M. kansasii. The positive rates of IGRAs are 25.9–33.3% while in patients without the previous TB the rates are as low as 18.8–20.0%. The multivariate analysis revealed that the factor contributing to positive IGRAs was only the previous TB, suggesting that T cell response to CFP-10 and ESAT-6 in patients with M. kansasii infection alone might be weak. Previous TB infection potentiated the IFN-γ

Conclusion

The positive rate of IGRAs for TB in patients with M. kansasii was lower than that in patients with active TB, suggesting weak cross-reactivity of TB specific antigens in patients with M. kasasii. Past TB infection significantly affects the IGRA positivity in these patients.

Conflict of interest

None.

References (30)

  • R.M. Thomson et al.

    Changing epidemiology of pulmonary nontuberculous mycobacteria infections

    Emerg Infect Dis

    (2010)
  • S.M. Moon et al.

    Clinical significance of Mycobacterium kansasii isolates from respiratory specimens

    PLoS One

    (2015)
  • S.M. Arend et al.

    ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii

    J Infect Dis

    (2005)
  • Y.G. Hur et al.

    Identification of immunological biomarkers which may differentiate latent tuberculosis from exposure to environmental nontuberculous mycobacteria in children

    Clin Vaccine Immunol

    (2014)
  • D.E. Griffith et al.

    An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

    Am J Respir Crit Care Med

    (2007)
  • Cited by (15)

    • Diagnostic accuracy of the interferon-gamma release assay (IGRA) for cases of feline mycobacteriosis

      2021, Preventive Veterinary Medicine
      Citation Excerpt :

      Studies in humans have investigated the use of M. avium-sensitin to improve sensitivity for diagnosing M. avium-complex infections (Ra et al., 2011), but IGRAs typically perform poorly for diagnosing NTM infections (Lein et al., 1999; Ra et al., 2011). It has also been shown that NTM infections in humans can give false-positive results on IGRA testing for TB (Hermansen et al., 2014); typically these cross-reactive NTM, which includes M. kansasii (Sato et al., 2016), are RD-1-positive (Guinn et al., 2004; Arend et al., 2005; van Ingen et al., 2009). These RD-1 orthologues have been shown to generate a quantifiable T-cell response in cattle, but this immune response is less potent than for M. bovis (Vordermeier et al., 2007).

    View all citing articles on Scopus
    View full text